Cambridge Investment Research Advisors
NVIV

Cambridge Investment Research Advisors’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Cambridge Investment Research Advisors’s Portfolio NVIV Stock Details NVIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1
Closed -$28K – 2192
2017
Q3 		$28K Hold
1
– – ﹤0.01% 1973
2017
Q2 		$52K Hold
1
– – ﹤0.01% 1881
2017
Q1 		$78K Hold
1
– – ﹤0.01% 1712
2016
Q4 		$81K Hold
1
– – ﹤0.01% 1599
2016
Q3 		$132K Hold
1
– – ﹤0.01% 1642
2016
Q2 		$71K Hold
1
– – ﹤0.01% 1505
2016
Q1 		$73K Hold
1
– – ﹤0.01% 1534
2015
Q4 		$76K Hold
1
– – ﹤0.01% 1506
2015
Q3 		$91K Buy
+1
New +$234K ﹤0.01% 1366

Other funds holding NVIV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ICM
IMS Capital Management Portland, Oregon $217M AUM 18.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Cambridge Investment Research Advisors's NVIV Position: Q4 2017 in Review

Cambridge Investment Research Advisors sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q4 2017, closing a stake of 1 share — an estimated $28K sold.

Cambridge Investment Research Advisors first reported a position in NVIV in Q3 2015 and held it in 9 quarters. The position peaked at $132K in Q3 2016. 28 funds tracked by Wall St. Rank hold NVIV as of Q4 2017.

  • Cambridge Investment Research Advisors reported no remaining InVivo Therapeutics Holdings Corp position as of Q4 2017 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 1 InVivo Therapeutics Holdings Corp share in Q4 2017, an estimated $28K.
  • Cambridge Investment Research Advisors first reported a position in InVivo Therapeutics Holdings Corp in Q3 2015 and held it in 9 quarters.
  • Cambridge Investment Research Advisors's InVivo Therapeutics Holdings Corp position peaked at $132K in Q3 2016.
  • 28 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q4 2017.

Based on Cambridge Investment Research Advisors's 13F filing for Q4 2017, filed 22 Feb 2018.